Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Lucy Scientific Discovery Inc. (LSDIF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: LSDIF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -11.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.01M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 5540 | Beta -11.56 | 52 Weeks Range 0.00 - 2.16 | Updated Date 02/26/2025 |
52 Weeks Range 0.00 - 2.16 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8906.54% |
Management Effectiveness
Return on Assets (TTM) -99.35% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2010941 | Price to Sales(TTM) 0.53 |
Enterprise Value 2010941 | Price to Sales(TTM) 0.53 | ||
Enterprise Value to Revenue 120.19 | Enterprise Value to EBITDA -9.52 | Shares Outstanding 1764760 | Shares Floating 1460178 |
Shares Outstanding 1764760 | Shares Floating 1460178 | ||
Percent Insiders 18.03 | Percent Institutions 6.33 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lucy Scientific Discovery Inc.
Company Overview
History and Background
Lucy Scientific Discovery Inc. was founded in 2021 and focuses on developing and manufacturing psychedelic compounds. It seeks to address the growing demand for psychedelics in medical research and therapeutic applications.
Core Business Areas
- Psychedelic Compound Manufacturing: Specializes in the production of high-quality psychedelic compounds like psilocybin, mescaline, and LSD, catering to research and pharmaceutical companies.
- Research and Development: Conducts in-house research to develop novel psychedelic formulations and optimize existing compounds for therapeutic use.
- API Sales: The company sells their Active Pharmaceutical Ingredients (APIs) to researchers, pharmaceutical companies, and other B2B customers.
Leadership and Structure
The leadership team consists of seasoned executives with experience in pharmaceuticals, chemistry, and business management. The organizational structure is designed to facilitate efficient R&D and manufacturing operations.
Top Products and Market Share
Key Offerings
- Psilocybin: High-quality psilocybin used in clinical trials for depression, anxiety, and PTSD. Market share data is not readily available, but the demand is increasing. Competitors include other API manufacturers and companies developing psilocybin-based therapies.
- Mescaline: Pharmaceutical-grade mescaline for research purposes. Market share data is limited, and competitors include companies specializing in natural product extraction and synthesis of mescaline analogs.
- LSD: Manufactures LSD for sale as an API for research purposes. Market share data is limited, and competitors include companies specializing in research chemicals.
Market Dynamics
Industry Overview
The psychedelic drug industry is rapidly evolving, driven by increasing research into the therapeutic potential of psychedelics for various mental health conditions.
Positioning
Lucy Scientific Discovery Inc. is positioned as a key supplier of high-quality psychedelic compounds, enabling research and development in the field. Its competitive advantage lies in its focus on quality, purity, and regulatory compliance.
Total Addressable Market (TAM)
The total addressable market for psychedelic compounds is estimated in the billions of dollars, with growth expected in the coming years. Lucy Scientific Discovery Inc. aims to capture a significant share of this market by serving as a reliable supplier of APIs.
Upturn SWOT Analysis
Strengths
- Specialized Expertise in Psychedelic Compound Synthesis
- Focus on High-Quality and Purity
- Strong Relationships with Research Institutions
- Early Mover Advantage
Weaknesses
- Limited Financial Resources
- Small Scale of Operations
- Dependence on Regulatory Approvals
- Limited Brand Recognition
Opportunities
- Expanding Market for Psychedelic Therapies
- Strategic Partnerships with Pharmaceutical Companies
- Increasing Investment in Psychedelic Research
- Potential for Product Diversification
Threats
- Regulatory Uncertainty
- Competition from Established Pharmaceutical Companies
- Ethical Concerns Regarding Psychedelic Use
- Price Volatility of Raw Materials
Competitors and Market Share
Key Competitors
- GHSI
- NUMI
- MNMD
- CMPS
Competitive Landscape
Lucy Scientific Discovery Inc. faces competition from established pharmaceutical companies and other companies specializing in psychedelic compound manufacturing. The company's success depends on its ability to differentiate itself through product quality, regulatory compliance, and strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not available due to the company's recent inception.
Future Projections: Future growth is dependent on regulatory approvals, market adoption of psychedelic therapies, and the company's ability to secure financing.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, developing new formulations, and building relationships with key stakeholders.
Summary
Lucy Scientific Discovery Inc. is a relatively new player in the emerging psychedelic drug market, and is competing against far larger publicly traded and private companies. Its focus on high-quality psychedelic compound manufacturing positions it well to serve the growing demand for these substances in research and therapeutic applications. However, the company faces significant challenges, including regulatory uncertainty, competition from established players, and the need to secure additional financing. Its success will depend on its ability to navigate these challenges and capitalize on the opportunities in the evolving psychedelic market.
Similar Companies
CMPS
Compass Pathways Plc
CMPS
Compass Pathways Plc
GHSI
Guardion Health Sciences Inc
GHSI
Guardion Health Sciences Inc
MNMD
Mind Medicine Inc
MNMD
Mind Medicine Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Industry Reports
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Market share figures are estimates and may vary. The psychedelic drug market is subject to regulatory changes and ethical considerations. This analysis is based on available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lucy Scientific Discovery Inc.
Exchange NASDAQ | Headquaters Victoria, BC, Canada | ||
IPO Launch date 2023-02-09 | CEO & Executive Chair Mr. Richard D. Nanula | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.lucyscientific.com |
Full time employees 2 | Website https://www.lucyscientific.com | ||
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.